|
IL36670A
(en)
|
1971-04-21 |
1974-09-10 |
Sela M |
Therapeutic basic copolymers of amino acids
|
|
US5800808A
(en)
|
1994-05-24 |
1998-09-01 |
Veda Research And Development Co., Ltd. |
Copolymer-1 improvements in compositions of copolymers
|
|
IL119989A0
(en)
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
|
US6214791B1
(en)
|
1997-01-10 |
2001-04-10 |
Yeda Research And Development Co. Ltd. |
Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
|
|
ES2527760T3
(es)
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
|
IL141021A0
(en)
|
1998-07-23 |
2002-02-10 |
Yeda Res & Dev |
Treatment of autoimmune conditions with copolymer 1 and related copolymers
|
|
WO2000005249A2
(en)
|
1998-07-23 |
2000-02-03 |
The President And Fellows Of Harvard College |
Synthetic peptides and methods of use for autoimmune disease therapies
|
|
US6800287B2
(en)
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
HU229719B1
(en)
|
1998-09-25 |
2014-05-28 |
Yeda Res & Dev |
Copolymer-1-delated polipeptides for use as molecular weight markers and for therapeutic use
|
|
AU6281599A
(en)
|
1998-10-02 |
2000-04-26 |
Yeda Research And Development Co. Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
|
CA2355400A1
(en)
|
1998-11-12 |
2000-05-18 |
Yeda Research And Development Co., Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
|
|
ES2243450T3
(es)
|
2000-01-20 |
2005-12-01 |
Yeda Research And Development Co. Ltd. |
El uso de copolimero 1 y peptidos y polipeptidos relacionados, y de celulas t tratadas con los mismos, para terapia neuroprotectora.
|
|
WO2001060392A1
(en)
|
2000-02-18 |
2001-08-23 |
Yeda Research And Development Co., Ltd. At The Weizmann Institute Of Science |
Oral, nasal and pulmonary dosage formualtions of copolymer 1
|
|
US7022663B2
(en)
|
2000-02-18 |
2006-04-04 |
Yeda Research And Development Co., Ltd. |
Oral, nasal and pulmonary dosage formulations of copolymer 1
|
|
IL153236A0
(en)
|
2000-06-05 |
2003-07-06 |
Teva Pharma |
The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
US20020077278A1
(en)
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
MXPA02007109A
(es)
|
2000-06-07 |
2002-12-13 |
Yeda Res & Dev |
El uso del copolimero 1 y peptidos y polipeptidos relacionados y celulas t tratadas con estos para proteger a las celulas del sistema nervioso central de la toxicidad del glutamato.
|
|
WO2002076503A1
(en)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
|
CA2469393C
(en)
|
2001-12-04 |
2010-05-25 |
Teva Pharmaceutical Industries, Ltd. |
Processes for the measurement of the potency of glatiramer acetate
|
|
EP1429800B1
(en)
|
2001-12-06 |
2009-02-11 |
Yeda Research And Development Co., Ltd. |
Vaccine and use thereof for treatment of amyotrophic lateral sclerosis
|
|
US7507531B2
(en)
|
2002-10-17 |
2009-03-24 |
Decode Genetics Chf. |
Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
|
|
US20080293750A1
(en)
|
2002-10-17 |
2008-11-27 |
Anna Helgadottir |
Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
|
|
US20060019269A1
(en)
|
2002-10-17 |
2006-01-26 |
Decode Genetics, Inc. |
Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
|
|
US7851486B2
(en)
|
2002-10-17 |
2010-12-14 |
Decode Genetics Ehf. |
Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
|
|
EP1565486A2
(en)
|
2002-11-13 |
2005-08-24 |
Apotex Pharmachem Inc. |
Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
|
|
JP5291878B2
(ja)
|
2003-01-07 |
2013-09-18 |
イエダ リサーチ アンド デベロップメント カンパニー リミテッド |
治療的免疫のためのコポリマー１を含む点眼ワクチン
|
|
NZ569331A
(en)
|
2003-01-21 |
2010-08-27 |
Yeda Res & Dev |
COP 1 for treatment of inflammatory bowel diseases
|
|
CA2518079A1
(en)
|
2003-03-04 |
2004-10-28 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
|
PT1638589E
(pt)
|
2003-05-14 |
2014-06-12 |
Teva Pharma |
Terapia combinada com acetato de glatirâmero e mitoxantrona para o tratamento da esclerose múltipla
|
|
US20050064483A1
(en)
*
|
2003-08-28 |
2005-03-24 |
Baylor College Of Medicine |
Gene expression profiling technology for treatment evaluation of multiple sclerosis
|
|
CA2540701A1
(en)
|
2003-09-29 |
2005-04-07 |
Chugai Seiyaku Kabushiki Kaisha |
Proteins expressed in nk cells
|
|
JP2007509981A
(ja)
|
2003-10-31 |
2007-04-19 |
テバ ファーマシューティカル インダストリーズ リミティド |
薬物デリバリー用ナノ粒子
|
|
AU2004288654B2
(en)
|
2003-11-12 |
2009-12-03 |
Yeda Research And Development Co. Ltd. |
Vaccine and method for treatment of neurodegenerative diseases
|
|
US20100216863A1
(en)
|
2004-01-30 |
2010-08-26 |
Decode Genetics Ehf. |
Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
|
|
CA2553928A1
(en)
|
2004-01-30 |
2005-08-18 |
Decode Genetics Ehf. |
Susceptibility gene for myocardial infarction, stroke, and paod; methods of treatment
|
|
US20050266432A1
(en)
*
|
2004-02-26 |
2005-12-01 |
Illumina, Inc. |
Haplotype markers for diagnosing susceptibility to immunological conditions
|
|
EP1778286A4
(en)
|
2004-03-03 |
2009-04-08 |
Teva Pharma |
COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
|
|
US20050266410A1
(en)
|
2004-05-19 |
2005-12-01 |
Emily Walsh |
Methods of Human Leukocyte Antigen typing by neighboring single nucleotide polymorphism haplotypes
|
|
KR101347562B1
(ko)
|
2004-06-25 |
2014-01-03 |
더 브리검 앤드 우먼즈 하스피털, 인크. |
신경계 장애의 치료를 위한 조성물 및 방법
|
|
US20090048181A1
(en)
|
2004-09-02 |
2009-02-19 |
Schipper Hyman M |
Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
|
|
WO2006029411A2
(en)
|
2004-09-09 |
2006-03-16 |
Yeda Research And Development Co. Ltd. |
Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
|
|
DE602005018800D1
(de)
|
2004-09-09 |
2010-02-25 |
Teva Pharma |
Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure
|
|
CA2583589C
(en)
|
2004-10-29 |
2012-04-24 |
Sandoz Ag |
Processes for preparing glatiramer
|
|
RU2419638C2
(ru)
|
2005-02-02 |
2011-05-27 |
Тева Фармасьютикал Индастриз, Лтд. |
Способ получения полипептидных смесей с использованием гидрогенолиза
|
|
RS52867B
(sr)
|
2005-02-17 |
2013-12-31 |
Teva Pharmaceutical Industries Ltd. |
Kombinovana terapija glatiramer acetatom i razagilinom za lečenje multiple skleroze
|
|
US20100167983A1
(en)
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
CA2606194A1
(en)
|
2005-04-25 |
2006-11-02 |
Yeda Research And Development Company |
Markers associated with the therapeutic efficacy of glatiramer acetate
|
|
WO2007030573A2
(en)
|
2005-09-09 |
2007-03-15 |
Yeda Research And Development Co. Ltd. |
Polypeptides useful for molecular weight determinations
|
|
US20070161566A1
(en)
*
|
2006-01-11 |
2007-07-12 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
|
US20080118553A1
(en)
|
2006-06-12 |
2008-05-22 |
Anton Frenkel |
Tannate salt form of polypeptide mixtures, their preparation and use
|
|
ATE452140T1
(de)
|
2006-07-05 |
2010-01-15 |
Momenta Pharmaceuticals Inc |
Verbessertes verfahren zur herstellung von copolymer-1
|
|
US20080131887A1
(en)
*
|
2006-11-30 |
2008-06-05 |
Stephan Dietrich A |
Genetic Analysis Systems and Methods
|
|
US7795033B2
(en)
|
2007-03-19 |
2010-09-14 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methods to predict the outcome of treatment with antidepressant medication
|
|
CN101877963A
(zh)
|
2007-11-28 |
2010-11-03 |
泰华制药工业有限公司 |
延缓临床确诊的多发性硬化症发作的方法
|
|
US20090177487A1
(en)
|
2008-01-07 |
2009-07-09 |
Tera Eerkes |
Methods for Assessing Genetic Compatibility
|
|
US20110158979A1
(en)
|
2008-06-13 |
2011-06-30 |
Prognomix, Inc. |
Genetic component of complications in type 2 diabetes
|
|
AU2009266947A1
(en)
|
2008-07-04 |
2010-01-07 |
Axial Biotech, Inc |
Genetic markers associated with degenerative disc disease and uses thereof
|
|
WO2010103292A2
(en)
*
|
2009-03-12 |
2010-09-16 |
Brainco Biopharma S.L. |
A genotyping tool for improving the prognostic and clinical management of ms patients
|
|
US20120073585A1
(en)
|
2009-04-08 |
2012-03-29 |
Cedars-Sinai Medical Center |
Methods of predicting complication and surgery in crohn's disease
|
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
|
DK2275086T3
(da)
|
2009-07-15 |
2012-07-09 |
Teva Pharma |
Reduceret volumenformulering af glatirameracetat og fremgangsmåder til administration heraf
|
|
DK2405749T3
(da)
|
2009-08-20 |
2013-07-15 |
Yeda Res & Dev |
Lavfrekvent glatiramer-acetat-terapi
|
|
US8853378B2
(en)
|
2009-10-09 |
2014-10-07 |
Georgetown University |
Polynucleotides that home to atherosclerotic plaque
|
|
US8759302B2
(en)
*
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
|
AU2011313842B2
(en)
|
2010-10-11 |
2016-12-15 |
Teva Pharmaceutical Industries Ltd. |
Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
|
|
BR112014008752A2
(pt)
|
2011-10-10 |
2017-04-25 |
Teva Pharma |
polimorfismos de nucleotídeos singulares úteis para predizer a resposta clínica para acetato de glatirâmero
|
|
MX2015004563A
(es)
|
2012-10-10 |
2015-07-14 |
Teva Pharma |
Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
|
|
EP2934493A4
(en)
|
2012-12-21 |
2016-09-07 |
Teva Pharma |
ORAL TRANSMUCOSAL ADMINISTRATION OF GLATIRAMERACETATE
|
|
HK1214523A1
(zh)
|
2012-12-21 |
2016-07-29 |
Teva Pharmaceutical Industries Ltd. |
醋酸格拉替雷的透粘膜给药
|
|
BR112015016169A2
(pt)
|
2013-01-04 |
2017-07-11 |
Teva Pharma |
caracterizando produtos de drogas relacionados a acetato de glatirâmero
|
|
CN105188751A
(zh)
|
2013-03-12 |
2015-12-23 |
泰华制药工业有限公司 |
利妥昔单抗诱导疗法继而醋酸格拉替雷疗法
|
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|